Severe hyperammonaemia in adults not explained by liver disease

Annals of Clinical Biochemistry

Volumn 49, Issue 3, 2012, Pages 214-228

  Walker, Valerie ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTICONVULSIVE AGENT; FATTY ACID; GLUTAMIC ACID DERIVATIVE; GLUTAMINE; N CARBAMYL L GLUTAMIC; OROTIC ACID; SALICYLIC ACID; UNCLASSIFIED DRUG; VALPROIC ACID;

ACIDURIA; ADAPTATION; AMINO ACID METABOLISM; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CHEMOTHERAPY; DELAYED DIAGNOSIS; DETOXIFICATION; DISEASE SEVERITY; EPILEPSY; FATTY ACID OXIDATION; HUMAN; HYPERAMMONEMIA; HYPERORNITHINEMIA; HYPERORNITHINEMIA HYPERAMMONEMIA HOMOCITRULLINURIA SYNDROME; LEUKEMIA; LIVER DISEASE; LYSINURIC PROTEIN INTOLERANCE; MOOD DISORDER; MULTIPLE MYELOMA; MYXEDEMA; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TOXICITY; TREATMENT OUTCOME; UREA CYCLE; URINARY TRACT DISEASE; URINE;

ADULT; AMINO ACIDS; AMMONIA; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; GLUTAMINE; HUMANS; HYPERAMMONEMIA; LIVER; LIVER DISEASES; NITROGEN; UREA; UREA CYCLE DISORDERS, INBORN;

EID: 84861498443     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011206     Document Type: Review

References (137)

1. Cooper AJL, Plum P. Biochemistry and physiology of brain ammonia. Physiol Rev 1987;67:440-519
2. Walker V. Ammonia toxicity and its prevention in inherited defects of the urea cycle. Diabetes Obes Metab 2009;11:823-35
3. Olde Damink SWM, Jalan R, Dejong CHC. Interorgan trafficking in liver disease. Metab Brain Dis 2009;24:169-81
4. Wright G, Noiret L, Olde Damink SWM, Jalan R. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int 2011;31:163-75
5. Butterworth RF. Effects of hyperammonaemia on brain function. J Inherit Metab Dis 1998;21(Suppl. 1):6-20
6. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002;67:259-79
7. Windmueller HG. Glutamine utilization by the small intestine. In: Meister A, ed. Advances in Enzymology. New York: John Wiley, 1982: 201-37
8. Mounger EJ, Branson AD. Ammonia encephalopathy secondary to ureterosigmoidostomy: a case report. J Urol 1972;108:411-2
9. Jungermann K. Functional heterogeneity of periportal and perivenous hepatocytes. Enzyme 1986;35:161-80
10. Meijer AJ, Lamers WH, Chamuleau RAFM. Nitrogen metabolism and ornithine cycle function. Physiol Rev 1990;70:701-48
11. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 1996;43:127-70
12. Brusilow SW, Horwich AL. Urea cycle enzymes. In: Scriver CR, Beaudet D, Valle D, Sly WS, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th edn. New York: McGraw-Hill, 2001:1909-61
13. Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. J Pediatr 2001;138(Suppl.):S6-10
14. Brosnan ME, Brosnan JT. Orotic acid excretion and arginine metabolism. J Nutr 2007;137:1656S-61S
15. Pita AM, Fernandez-Bustos A, Rodes M, et al. Orotic aciduria and plasma urea-cycle-related amino acid alterations in short bowel syndrome, evoked by an arginine-free diet. JPEN 2004;28:315-23
16. Bosoi CR, Rose CF. Identifying the direct effects of ammonia on the brain. Metab Brain Dis 2009;24:95-102
17. Clay AS, Hainline BE. Hyperammonemia in the ICU. Chest 2007;132:1368-78
18. Cascino GD, Jensen JM, Nelson LA, Schutta HS. Periodic hyperammonemic encephalopathy associated with a ureterosigmoidostomy. Mayo Clin Proc 1989;64:653-6
19. Michalak A, Butterworth RF. Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy. Metab Brain Dis 1997;12:171-82
20. Hawkes ND, Thomas GAO, Jurewicz A, et al. Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J 2001;77:717-22
21. Nassogne MC, Héron B, Touati G, Rabier D, Saudubray JM. Urea cycle defects: management and outcome. J Inherit Metab Dis 2005;28:407-14
22. Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. J Inherit Metab Dis 2007;30:865-9
23. Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr 2008;97:1420-5
24. Lichter-Konecki U. Profiling of astrocyte properties in the hyperammonaemic brain: shedding new light on the pathophysiology of the brain damage in hyperammonaemia. J Inherit Metab Dis 2008;31:492-502
25. Gropman A. Brain imaging in urea cycle disorders. Mol Genet Metab 2010;100(Suppl. 1):S20-30
26. Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006;44:788-94
27. Basile AS. Direct and indirect enhancement of GABAergic neurotransmission by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Neurochem Int 2002;41:115-22
28. Bachmann C, Braissant O, Villard A-M, Boulat O, Henry H. Ammonia toxicity to the brain and creatine. Mol Genet Metab 2004;81:S52-7
29. Stanley CA. Hyperinsulinism/hyperammonemia syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolism. Mol Genet Metab 2004;81(Suppl. 1):S45-51
30. Wilcken B. Problems in the management of urea cycle disorders. Mol Genet Metab 2004;81:S86-91
31. Chakrapani A, Champion M, Grunewald S, et al. Experience of urea cycle disorders in the United Kingdom. J Inherit Metab Dis 2010;33(Suppl. 1):S119
32. Tuchman M, Lee B, Lichter-Konecki U, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 2008;94:397-402
33. Leonard JV. Disorders of the urea cycle and related enzymes. In: Saudubray J-M, van den Berghe G, Walter JH, eds. Inborn Metabolic Diseases. 4th edn. Heidelberg: Springer Medizin Verlag, 2006: 263-72
34. Tuchman M, Jaleel N, Morizono H, Sheehy L, Lynch MG. Mutations and polymorphisms in the human ornithine transcarbamylase gene. Hum Mutat 2002;19:93-107
35. Maestri NE, Lord CR, Glynn M, Bale A, Brusilow SW. The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine 1998;77:389-97
36. Gyato K, Wray J, Huang ZJ, Yudkoff M, Batshaw ML. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann Neurol 2004;55:80-6
37. Yu R, Potter M. Diagnosis of urea cycle disorders in adulthood: late-onset carbamyl phosphate synthetase I deficiency. McMaster Univ Med J 2010;7:30-32. See www.mumj.org/Issues/v7_2010/articles/ (last checked 8 July 2011)
38. Klein OD, Kostiner DR, Weisiger K, et al. Acute fatal presentation of ornithine transcarbamylase deficiency in a previous healthy male. Hepatol Int 2008;2:390-4
39. Ben-Ari Z, Dalai A, Morry A, et al. Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet. J Hepatol 2010;52:292-5
40. Panlaqui OM, Tran K, Johns A, McGill J, White H. Acute hyperammonemic encephalopathy in adult onset ornithine transcarbamylase deficiency. Intensive Care Med 2008;34:1922-4
41. Cavicchi C, Morrone A, Parini R, et al. OTC gene mutations associated with fatal hyperammonemia in previously healthy adult patients. J Inherit Metab Dis 2010;33(Suppl. 1):S120
42. Hu WT, Kantarci OH, Merritt JL II, et al. Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery. Arch Neurol 2007;64:126-8
43. Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin 2005;21(Suppl.):S1-8
44. Weng TI, Shih FF, Chen WJ. Unusual causes of hyperammonemia in the ED. Am J Emerg Med 2004;22:105-7
45. Bélanger-Quintana A, Martinez-Pardo M, Garcia MJ, et al. Hyperammonaemia as a cause of psychosis in an adolescent. Eur J Pediatr 2003;162:773-5
46. Plöchl W, Spiss CK, Plöchl E. Death after transplantation of a liver from a donor with unrecognized ornithine transcarbamylase deficiency. N Engl J Med 1999;341:921-2
47. Ryder KW, Olson JF, Kahnoski RJ, Karn RC, Oei TO. Hyperammonemia after transurethral resection of the prostate: a report of 2 cases. J Urol 1984;132:995-7
48. Cordero DR, Baker J, Dorinzi D, Toffle R. Ornithine transcarbamylase deficiency in pregnancy. J Inherit Metab Dis 2005;28:237-40
49. Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. New Engl J Med 1990;322;1652-5
50. Peterson DE. Acute postpartum mental status change and coma caused by previously undiagnosed ornithine transcarbamylase deficiency. Obstet Gynaecol 2003;102:1212-5
51. Tihtonen K, Uotila J, Lähde J, Salo M, Keskinen P. Risk of hyperammonemic coma in the puerperium: two cases of women with diagnosed and undiagnosed deficiency of urea cycle enzymes. Acta Obstet Gynecol Scand 2010;89:404-6
52. Online Mendelian Inheritance in Man. Hyperornithinemiahyperammonemia-homocitrullinuria syndrome. MIM ID#238970. See http://omim.org/entry/238970 (last checked 8 July 2011)
53. Tuchman M, Knopman DS, Shih VE. Episodic hyperammonemia in adult siblings with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Arch Neurol 1990;47:1134-7
54. Online Mendelian Inheritance in Man. Lysinuric protein intolerance. MIM ID # 222700. See http://www.omim.org/entry/222700 (last checked 8 July 2011)
55. Shaw PJ, Dale G, Bates D. Familial lysinuric protein intolerance presenting as coma in two siblings. J Neurol Neurosurg Psych 1989;52:648-51
56. McManus DT, Moore R, Hill CM, Rodgers C, Carson DJ, Love AH. Necropsy findings in lysinuric protein intolerance. J Clin Pathol 1996;49:345-7
57. Gare M, Shalit M, Gutman A. Lysinuric protein intolerance presenting as coma in a middle-aged man. West J Med 1996;165:231-3
58. Kobayashi K, Saheki T. Citrin deficiency. GeneReviews. See http://www.ncbi.nlm.nih.gov/books/NBK1181/ (last update 2008, last checked 8 July 2011)
59. Hauser ER, Finkelstein JE, Valle D, Brusilow SW. Allopurinol-induced orotidinuria. New Engl J Med 1990;322:1641-5
60. Grünewald S, Fairbanks L, Genet S, et al. How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency? J Inherit Metab Dis 2004;27:179-86
61. Steiner RD, Cederbaum SD. Laboratory evaluation of urea cycle disorders. J Pediatr 2001;138:S21-9
62. The Urea Cycle Disorders Conference Group. Consensus statement from a conference for the management of patients with urea cycle disorders. J Pediatr 2001;138(Suppl.):S1-5
63. Häberle J. Clinical practice: the management of hyperammonemia. Eur J Pediatr 2011;170:21-34.
64. Berry GT, Steiner D. Long-term management of patients with urea cycle disorders. J Pediatr 2001;138:S56-61
65. British Inherited Metabolic Disease Group. Guidelines; BIMDG emergency protocols. Hyperammonaemia: urea cycle disorders. BIMDG 2008. See http://www.bimdg.org.uk/protocols/topics.asp (last checked 8 July 2011)
66. Singh RH. Nutritional management of patients with urea cycle disorders. J Inherit Metab Dis 2007;30:880-7
67. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001;138(Suppl.):S46-55
68. Praphanphoj V, Boyadjiev SA, Waber LJ, Brusilow SW, Geraghty MT. Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia. J Inherit Metab Dis 2000;23:129-36
69. Weiner DL. Inborn errors of metabolism: treatment and medication 2009. See http://emedicine.medscape.com/article/804757-treatment (last checked 8 July 2011)
70. Lee B, Rhead W, Diaz GA, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 2010;100:221-8
71. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007;356:2282-92
72. Enns GM. Nitrogen sparing therapy revisited 2009. Mol Genet Metab 2010;100(Suppl. 1):S65-71
73. Daniotti M, La Marca G, Fiorini P, Filippi L. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int J General Med 2011;4:21-8
74. Leonard JV, McKiernan PJ. The role of liver transplantation in urea cycle disorders. Mol Genet Metab 2004;81:S74-8
75. Meyberg J, Das AM, Hoerster F, et al. One liver for four children: first clinical series of liver transplantation for severe neonatal urea cycle defects. Transplantation 2009;87:636-41
76. Gene therapy-a loss of innocence. Nat Med 2000;6:1
77. Ray PF, Gigarel N, Bonnefont JP, et al. First specific preimplantation genetic diagnosis for ornithine transcarbamylase deficiency. Prenat Diagn 2000;20:1048-54
78. Wanders RJA, Vreken P, den Boer MEJ, Wijburg FA, van Gennip AH, IJIst L. Disorders of mitochondrial fatty acyl-CoA b-oxidation. J Inherit Metab Dis 1999;22:442-87
79. Longo N, di San Filippo CA, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006;142C:77-85
80. Lang TF. Adult presentations of medium-chain acyl-CoA dehydrogenase deficiency (MCADD). J Inherit Metab Dis 2009;32:675-83
81. Roe CR. Diagnostic approach to disorders of fat oxidation for clinicians. FOD Support Group. See http://www.fodsupport.org/dx_fod.htm (last checked 8 July 2011)
82. Angelini C, Federico A, Reichmann H, Lombes A, Chinnery P, Turnbull D. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur J Neurol 2006;13:923-9
83. Schatz UA, Ensenauer R. The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population. J Inherit Metab Dis 2010;33:513-20
84. Kluge S, Kü hnelt P, Block A, et al. A young woman with persistent hypoglycemia, rhabdomyolysis, and coma: recognising fatty acid oxidation defects in adults. Crit Care Med 2003;31:1273-6
85. Stojanovic N, Walker V, Gatling W, Coppini DV. MADD or drunk? Adults have inborn errors too. Hosp Med 2000;61:212-3
86. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999;340:1723-31
87. Wanders RJA, Ruiter JPN, IJIst L, Waterham HR, Houten SM. The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results. J Inherit Metab Dis 2010;33:479-94
88. Coude FX, Sweetman L, Nyhan W. Inhibition by propionyl-coenzyme A of N-acetylglutamate synthetase in rat liver mitochondria. A possible explanation for hyperammonemia in propionic and methylmalonic academia. J Clin Invest 1979;64:1544-51
89. Coude FX, Grimber G, Parvy P, Rabier D. Role of N-acetylglutamate and acetyl-CoA in the inhibition of ureagenesis by isovaleric acid in isolated rat hepatocytes. Biochim Biophys Acta 1983;761:13-6
90. Fenton WA, Gravel RA, Rosenblatt DS. Disorders of propionate and methylmalonate metabolism. In: Scriver CR, Beaudet D, Valle D, Sly WS, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th edn. New York: McGraw-Hill, 2001:2165-93
91. Brown GK, Scholem RD, Hunt SM, Harrison JR, Pollard AC. Hyperammonaemia and lactic acidosis in a patient with pyruvate dehydrogenase deficiency. J Inherit Metab Dis 1987;10:359-66
92. Robinson BH. Lactic academia: disorders of pyruvate and pyruvate dehydrogenase. In: Scriver CR, Beaudet D, Valle D, Sly WS, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th edn. New York: McGraw-Hill, 2001:2275-95
93. Martín-Hernández E, Lee PJ, Micciche A, Grunewald S, Lachman RH. Long-term needs of adult patients with organic acidaemias: outcome and prognostic factors. J Inherit Metab Dis 2009;32:523-33
94. Shih VE, Aubry RH, DeGrande G, Gursky SF, Tanaka K. Maternal isovaleric acidemia. J Pediatr 1984;105:77-8
95. Weinberg GL, Laurito CE, Geldner P, Pygon BH, Burton BK. Malignant ventricular dysrhythmias in a patient with isovaleric acidemia receiving general and local anesthesia for suction lipectomy. J Clin Anaesth 1997;9:668-70
96. Wolf B, Norrgard K, Pomponio RJ, et al. Profound biotinidase deficiency in two asymptomatic adults. Am J Med Genet 1997;73:5-9
97. Baykal T, Gokcay G, Gokdemir Y, et al. Asymptomatic adults and older siblings with biotinidase deficiency ascertained by family studies of index cases. J Inherit Metab Dis 2005;28:903-12
98. Ah Mew N, McCarter R, Daikhin Y, Nissim I, Yudkoff M, Tuchman M. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic academia. Pediatrics 2010;126:e208-14
99. DeWolfe JL, Knowlton RC, Beasley MT, Cofield S, Faught E, Limdi NA. Hyperammonemia following intravenous valproate loading. Epilepsy Res 2009;85:65-71
100. Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 2007;20:499-502
101. Duarte J, Macias S, Coria F, Fernandez E, Claveria LE. Valproate-induced coma: case report and literature review. Ann Pharmacother 1993;27:582-3
102. Stefan M, Bavli S. Recurrent stupor associated with chronic valproic acid therapy and hyperammonemia. Hospital Physician 2009;45:17-20
103. LaBuzetta JN, Yao JZ, Bourque DL, Zivin J. Adult nonhepatic hyperammonemia: a case report and differential diagnosis. Am J Med 2010;123:885-91
104. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006;114:1-7
105. Kaveggia FF, Thompson JS, Schafer EC, Fischer JL, Taylor RJ. Hyperammonemic encephalopathy in urinary diversion with urea-splitting urinary tract infection. Arch Intern Med 1990;150:2389-92
106. Kuntze JR, Weinberg AC, Ahlering TE. Hyperammonemic coma due to proteus infection. J Urol 1985;134:972-3
107. Koch MO, McDougal WS. The pathophysiology of hyperchloremic metabolic acidosis after urinary diversion through intestinal segments. Surgery 1985;98:561-70
108. Lora-Tamayo J, Palom X, Sarrá J, et al. Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases. Clin Lymphoma Myeloma 2008;8:363-9
109. Watson AJ, Chambers T, Karp JE, Risch VR, Walker WG, Brusilow SW. Transient idiopathic hyperammonaemia in adults. Lancet 1985;326:1271-4
110. Nott L, Price TJ, Pittman K, Patterson K, Fletcher J. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma 2007;48:1702-11
111. Leonard JV, Kay JDS. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 1986;327:162-3
112. Doloy A, Roy S, Djoussa-Kambou S, Legrand F, Brion F, Rieutord A. The use of sodium benzoate in a ten-fold overdose of asparaginase. Paediatr Parenteral Drug Therapy 2002;5:59-64
113. Jörck C, Kiess W, Weigel JF, Mütze U, Bierbach U, Beblo S. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Pediatr Haematol Oncol 2011;28:3-9
114. Liaw CC, Liaw SJ, Wang CH, Chiu MC, Huang JS. Transient hyperammonemia related to chemotherapy with continuous infusion of high dose 5-fluorouracil. Anticancer Drugs 1993;4:311-5
115. Kim S-R, Park C-H, Park S, Park J-O, Lee J, Lee S-Y. Genetic polymorphisms associated with 5-fluorouracil-induced neurotoxicity. Chemotherapy 2010;56:313-7
116. Adams EN, Marks A, Lizer MH. Carbamazepine-induced hyperammonemia. Am J Health-System Pharmacy 2009;66:1468-70
117. Hall SM. Reye's syndrome and aspirin: a review. Br J Clin Pract 1990;44(Suppl. 70):4-11
118. Rowe PC, Valle D, Brusilow SW. Inborn errors of metabolism in children referred with Reye's syndrome. A changing pattern. JAMA 1988;260:3167-70
119. Orlowski JP. Whatever happened to Reye's syndrome? Did it ever really exist? Crit Care Med 1999;27:1582-7
120. Deschamps D, Fisch C, Fromenty B, Berson A, Degott C, Pessayre D. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 1991;259:894-904
121. Glasgow JFT, Middleton B, Moore R, Gray A, Hill J. The mechanism of inhibition of b-oxidation by aspirin metabolites in skin fibroblasts from Reye's syndrome patients and controls. Biochim Biophys Acta 1999;1454:115-25
122. Battaglia V, Salvi M, Toninello A. Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria. J Biol Chem 2005;280:33864-72
123. Welsh E, Kucera J, Perloff MD. Iatrogenic hyperammonemia after anorexia. Arch Intern Med 2010;170:486-8
124. Hamilton Stewart PA, Barlow IM. Metabolic effects of prostatectomy. J R Soc Med 1989;82:725-8
125. Thobe N, Pilger P, Jones MP. Primary hypothyroidism masquerading as hepatic encephalopathy: case report and review of the literature. Postgrad Med J 2000;76:424-6
126. Rimar D, Kruzel-Davila E, Dori G, Baron E, Bitterman H. Hyperammonemic coma-barking up the wrong tree. J Gen Intern Med 2007;22:549-52
127. Howanitz JH, Howanitz PJ, Skrodzki CA, Iwanski JA. Influences of specimen processing and storage conditions on results for plasma ammonia. Clin Chem 1984;30:906-8
128. da Fonseca-Wollheim F. Preanalytical increase of ammonia in blood specimens from healthy subjects. Clin Chem 1990;36:1483-7
129. Barsotti RJ. Measurement of ammonia in blood. J Pediatr 2001;138:S11-20
130. UK National Metabolic Biochemistry Network. Guidelines for the investigation of hyperammonaemia. See www.metbio.net (last checked July 2011)
131. Herrera DJ, Hutchin T, Fullerton D, Gray G. Non-specific interference in the measurement of plasma ammonia: importance of using a serum blank. Ann Clin Biochem 2010;47:81-3
132. Losty H. Blood ammonia meters-more than a flashy display. BIMDG Bull 2004;26:9-11
133. Cook P, Walker V. Investigation of the child with an acute metabolic disorder. J Clin Pathol 2011;64:181-91
134. McCann MT, Thompson MM, Gueron IC, Tuchman M. Quantification of orotic acid in dried filter-paper urine samples by stable isotope dilution. Clin Chem 1995;41:739-43
135. van Kuilenburg ABP, van Lenthe H, Löffler M, van Gennip AH. Analysis of pyrimidine synthesis 'de novo' intermediates in urine and dried urine filter-paper strips with HPLC-electrospray tandem mass spectrometry. Clin Chem 2004;50:2117-24
136. Turner C, Dalton RN. Measurement of orotic acid in plasma for the diagnosis of urea cycle disorders. J Inherit Metab Dis 2010;33(Suppl. 1):S121
137. Rizzo C, Boenzi S, Goffredo BM, et al. Rapid HPLC ESI-MS/MS method for the diagnosis of urea cycle defects. J Inherit Metab Dis 2010;33(Suppl. 1):S120